Clinical Trials Logo

Hyperlipidemias clinical trials

View clinical trials related to Hyperlipidemias.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05953064 Active, not recruiting - Clinical trials for Hypertriglyceridemia

Effects of DHA-NAT on Postprandial Lipidaemia in Healthy Male Subjects

FEAST
Start date: January 1, 2023
Phase: N/A
Study type: Interventional

This study is an investigator-initiated, randomised, double-blind, placebo-controlled, cross-over human trial investigating the effect of DHA-NAT (C22:6 N-acyl taurine, an endogenous metabolite derived from the omega-3 fatty acid, docosahexaenoic acid) on postprandial plasma triglyceride levels following a high-fat meal.

NCT ID: NCT05820295 Active, not recruiting - Stroke Clinical Trials

Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coordination

Start date: May 17, 2023
Phase: N/A
Study type: Interventional

This pragmatic clinical trial embedded in an accountable care organization will determine the comparative effectiveness of two approaches for assigning care coordinators to older adults at risk for cardiovascular outcomes. The hypothesis is that assigning care coordinators to older adults based on perceived need will be more effective at preventing emergency department visits and hospitalizations compared to usual care.

NCT ID: NCT05814419 Active, not recruiting - Clinical trials for Familial Hyperlipidemia

Familial Hyperlipidemia Family Registry

Start date: February 17, 2023
Phase:
Study type: Observational [Patient Registry]

The aim of the study is to identify children and families that are at risk for cardiovascular disease because of a condition known as familial hyperlipidemia. This condition may increase the risk of cardiac events such as hardening of the arteries anywhere in the body which can result in heart attacks, strokes, and death over ten fold. Children have already been assessed in the Healthy Hearts screening program and identified as having elevated cholesterol. A buccal smear will identify whether the familial hyperlipidemia condition exist in your child. If the child's test shows that they have the specific gene for familial hyperlipidemia and shows a genetic tendency towards premature heart disease, we would encourage genetic testing for as many blood family members as possible. The study plan is to determine whether the Healthy Hearts screening program is a more effective way of identifying students at risk since it is estimated that less than 10% of those individuals with the problem have been identified. If it is effective, then it will be incorporated as part of the standard screening process in the Healthy Hearts program. Aim 1: Is a school screening program a more effective method to identifying those at risk for familial hyperlipidemia? Aim 2: What percent of children with elevated cholesterol ≥ 200 mg/dl have familial hyperlipidemia?

NCT ID: NCT05537064 Active, not recruiting - Hyperlipidemias Clinical Trials

Centralized Prescribing for Statins

Start date: November 2, 2022
Phase: N/A
Study type: Interventional

This pilot study consists of a pair of pragmatic clinical trials that will evaluate two separate methods for optimizing referral of eligible patients to a centralized pharmacy service for statin management: 1) A stepped wedge clinical trial, with randomization at the level of the provider, evaluating a visit-based nudge for referral to pharmacy services versus usual care; 2) A cluster randomized trial, with randomization at the level of the practice, evaluating a non-visit based nudge for referral to pharmacy services versus usual care.

NCT ID: NCT05526092 Active, not recruiting - Clinical trials for Overweight and Obesity

OAT-GUT-BRAIN: Effects of Oats and Rice on Comprehensive Health of Metabolically Challenged Individuals

Start date: September 12, 2022
Phase: N/A
Study type: Interventional

The overall objective of this research entity is to reveal the holistic health impact of oats in metabolically challenged individuals in a 6-week intervention, compared to that of rice. This is achieved by investigation of the plasma lipids, plasma antioxidant status, fecal microbiota and fecal bile acids. Additionally the effect of the 6-week diet on posptprandial glycemia and postprandial satiety and vitality are investigated.

NCT ID: NCT05432544 Active, not recruiting - Hyperlipemia Clinical Trials

Safety and Tolerability of SHR-1918 in Healthy Subjects

Start date: June 27, 2022
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to assess the safety and tolerability of SHR-1918 injection in healthy subjects. In addition, this study will provide information on pharmacokinetics and pharmacodynamics of SHR-1918 injection in healthy subjects.

NCT ID: NCT05425745 Active, not recruiting - Clinical trials for Hypercholesterolemia

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

BROOKLYN
Start date: July 25, 2022
Phase: Phase 3
Study type: Interventional

This study will be a placebo-controlled, double-blind, randomized, phase 3 study to Evaluate the Efficacy, Safety, and Tolerability of Obicetrapib in Participants with a History of Heterozygous Familial Hypercholesterolemia (HeFH).

NCT ID: NCT05414851 Active, not recruiting - Hypertension Clinical Trials

Low-Carbohydrate and Plant-Based Dietary Effects on Vascular Health

Start date: December 20, 2022
Phase: N/A
Study type: Interventional

This is a randomized trial with a crossover design to investigate the short-term effects of two different dietary patterns on markers of vascular health. A low-carbohydrate diet and a whole-food, plant-based diet will be used. In addition to more traditional markers (cholesterol, blood pressure, inflammation), endothelial progenitor cells and trimethylamine N-oxide will be assessed.

NCT ID: NCT05326386 Active, not recruiting - Clinical trials for Hypertension and Hyperlipidemia

Gamification and Medication Adherence (GAME Adherence)

Start date: September 12, 2022
Phase: N/A
Study type: Interventional

A two-arm randomized controlled trial to evaluate whether a gamification intervention plus involvement of a supportive partner (social support) and sending reports to physicians (accountability) increases medication adherence in patients with hypertension and hyperlipidemia. The study will randomize 84 patients with hypertension, hyperlipidemia, and a history of poor medication adherence seen in a single Penn Medicine clinic to an 18-week gamification intervention or to attention control text messages alone.

NCT ID: NCT05305664 Active, not recruiting - Clinical trials for Hyperlipoproteinemia(a)

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany

Start date: August 19, 2022
Phase: Phase 3
Study type: Interventional

Phase III study to test the hypothesis that treatment with pelacarsen (TQJ230) 80 mg Q4W compared to placebo significantly reduces the rate of lipoprotein apheresis in patients with hyperlipoproteinemia (a) and established cardiovascular disease currently undergoing lipoprotein apheresis in Germany on a weekly schedule.